collection
MENU ▼
Read by QxMD icon Read
search

Adult Psychiatric Unit: Schizophrenia

shared collection
78 papers 500 to 1000 followers
By Edwin Kim Resident Physician, Aspiring Addiction Psychiatrist
https://www.readbyqxmd.com/read/28188887/neurobiological-underpinnings-and-modulating-factors-in-schizophrenia-spectrum-disorders-with-a-comorbid-substance-use-disorder-a-systematic-review
#1
REVIEW
Ana Adan, Arantxa Y Arredondo, Maria Del Mar Capella, Gemma Prat, Diego A Forero, José Francisco Navarro
Recently there is a growing interest in the interaction of schizophrenia spectrum disorders (SSD) and substance use disorders (SUD), a condition named dual schizophrenia spectrum disorders (SSD+). While previous research has focused on clinical and cognitive aspects, little is known about the impact of comorbidity in the brain structure and functions. Evidence suggests that dual diagnosis patients, including SSD+, show a better neurocognitive functioning during the first years of illness, followed by a serious long-term decline...
February 7, 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/21885577/substance-use-disorder-among-people-with-first-episode-psychosis-a-systematic-review-of-course-and-treatment
#2
REVIEW
Jennifer P Wisdom, Jennifer I Manuel, Robert E Drake
OBJECTIVE: People experiencing a first episode of psychosis frequently have co-occurring substance use disorders, usually involving alcohol and cannabis, which put them at risk for prolonged psychosis, psychotic relapse, and other adverse outcomes. Yet few studies of first-episode psychosis have addressed the course of substance use disorders and the response to specialized substance abuse treatments. METHODS: The authors searched MEDLINE, PsycINFO, and other medical databases for English-language articles published between 1990 and 2009...
September 2011: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/27863801/long-acting-injectable-antipsychotics-for-the-prevention-of-relapse-in-patients-with-recent-onset-psychotic-disorders-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#3
Taro Kishi, Kazuto Oya, Nakao Iwata
This meta-analysis of randomized controlled trials (RCTs) investigated the advantages of long-acting injectable antipsychotics (LAI-APs) over oral antipsychotics (OAPs) with regard to efficacy and safety for patients with recent-onset psychotic disorders. Effect sizes and 95% confidence intervals (95%CIs) were calculated. We identified five RCTs (1022 patients, mean study duration=18±7.59 months) that compared LAI-APs (paliperidone or risperidone) with OAPs. Pooled LAI-APs did not outperform OAPs in terms of the preventing of relapse (N=3, n=875)...
December 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/28112047/venous-thromboembolism-during-treatment-with-antipsychotics-results-of-a-drug-surveillance-program
#4
Martin Letmaier, Renate Grohmann, Christiana Kren, Sermin Toto, Stefan Bleich, Rolf Engel, Thomas Gary, Konstantinos Papageorgiou, Anastasios Konstantinidis, Anna Katharina Holl, Annamaria Painold, Siegfried Kasper
OBJECTIVES: Venous thromboembolism (VTE) can be a life-threatening medical condition that may lead to leg swelling, respiratory distress and death. METHODS: The AMSP (Arzneimittelsicherheit in der Psychiatrie) is a continuous multicenter drug surveillance program that assesses severe adverse drug reactions during treatment of psychiatric inpatients. We report on a total of 264,422 inpatients who were treated with antipsychotics (APs) and monitored from 1993 to 2011 in 99 psychiatric hospitals...
January 23, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/27282362/efficacy-and-safety-of-antidepressants-added-to-antipsychotics-for-schizophrenia-a-systematic-review-and-meta-analysis
#5
Bartosz Helfer, Myrto T Samara, Maximilian Huhn, Elisabeth Klupp, Claudia Leucht, Yikang Zhu, Rolf R Engel, Stefan Leucht
OBJECTIVE: The authors examined the safety and efficacy of antidepressants added to antipsychotic drugs in the treatment of schizophrenia. METHOD: Multiple databases and previous publications were searched through June 2015 to identify all randomized controlled trials of any add-on antidepressants compared with placebo or no-treatment in schizophrenia. Depressive and negative symptoms (primary outcomes), overall symptoms, positive symptoms, side effects, exacerbation of psychosis, and responder rates were examined...
September 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/24584988/adding-evidence-based-interventions-to-assertive-community-treatment-a-feasibility-study
#6
RANDOMIZED CONTROLLED TRIAL
Sjoerd Sytema, Frederike Jörg, Roeline Nieboer, Lex Wunderink
OBJECTIVE: This 24-month study, conducted in The Netherlands, examined the feasibility of enhancing the effectiveness of assertive community treatment (ACT) by adding evidence-based interventions. METHODS: A total of 159 patients were randomly assigned to two ACT teams, one providing standard ACT (N585) and an ACT Plus team that also provided evidence-based interventions (N574): psychoeducation, family interventions, individual placement and support, and cognitive behavioral therapy...
May 1, 2014: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/27919182/treatment-resistant-schizophrenia-treatment-response-and-resistance-in-psychosis-trrip-working-group-consensus-guidelines-on-diagnosis-and-terminology
#7
Oliver D Howes, Rob McCutcheon, Ofer Agid, Andrea de Bartolomeis, Nico J M van Beveren, Michael L Birnbaum, Michael A P Bloomfield, Rodrigo A Bressan, Robert W Buchanan, William T Carpenter, David J Castle, Leslie Citrome, Zafiris J Daskalakis, Michael Davidson, Richard J Drake, Serdar Dursun, Bjørn H Ebdrup, Helio Elkis, Peter Falkai, W Wolfgang Fleischacker, Ary Gadelha, Fiona Gaughran, Birte Y Glenthøj, Ariel Graff-Guerrero, Jaime E C Hallak, William G Honer, James Kennedy, Bruce J Kinon, Stephen M Lawrie, Jimmy Lee, F Markus Leweke, James H MacCabe, Carolyn B McNabb, Herbert Meltzer, Hans-Jürgen Möller, Shinchiro Nakajima, Christos Pantelis, Tiago Reis Marques, Gary Remington, Susan L Rossell, Bruce R Russell, Cynthia O Siu, Takefumi Suzuki, Iris E Sommer, David Taylor, Neil Thomas, Alp Üçok, Daniel Umbricht, James T R Walters, John Kane, Christoph U Correll
OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. METHOD: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus...
December 6, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27388573/clozapine-v-first-and-second-generation-antipsychotics-in-treatment-refractory-schizophrenia-systematic-review-and-meta-analysis
#8
REVIEW
Dan Siskind, Lara McCartney, Romi Goldschlager, Steve Kisely
BACKGROUND: Although clozapine is the 'gold standard' for treatment-refractory schizophrenia, meta-analyses of clozapine for this condition are lacking. AIMS: We conducted a systematic review and meta-analysis of clozapine treatment for people with treatment-refractory schizophrenia. METHOD: We searched the Cochrane Schizophrenia Group's trial register, PubMed and EMBASE and hand-searched key papers for randomised controlled trials of clozapine for treatment-refractory schizophrenia...
November 2016: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/26455671/recommendations-for-the-monitoring-of-serum-concentrations-of-antipsychotic-drugs-in-the-treatment-of-schizophrenia
#9
Leonardo V Lopez, John M Kane
No abstract text is available yet for this article.
September 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/23165366/efficacy-and-safety-of-second-generation-long-acting-injections-in-schizophrenia-a-meta-analysis-of-randomized-controlled-trials
#10
REVIEW
Paolo Fusar-Poli, Matthew J Kempton, Robert A Rosenheck
The aim of the present article is to test at a meta-analytical level the efficacy and safety of second-generation long-acting antipsychotic injections (SGLAI) in schizophrenia. Thirteen randomized-controlled trials comparing SGLAI with either placebo or oral antipsychotics were included in a quantitative meta-analysis (6313 patients). Efficacy and safety measures as well as demographic and clinical variables were extracted from each publication or obtained directly from authors. Publication bias was assessed with funnel plots and Egger's intercept...
March 2013: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/26720422/deconstructing-the-psychosis-risk-syndrome-moving-the-field-of-prevention-forward
#11
EDITORIAL
Barbara A Cornblatt, Ricardo E Carrión
No abstract text is available yet for this article.
February 2016: JAMA Psychiatry
https://www.readbyqxmd.com/read/9258854/integrating-substance-abuse-treatment-for-the-seriously-mentally-ill-into-inpatient-psychiatric-treatment
#12
REVIEW
C M Bradizza, P R Stasiewicz
This paper offers guidelines for the assessment and treatment of substance abuse problems in seriously mentally ill persons who are admitted into inpatient psychiatric treatment. This approach has been used successfully by the authors and may be most useful in settings where a specialized dual-diagnosis treatment program is not feasible. The first step consists of identifying potential substance abusers using several sources of information including the patient's record, a brief patient interview, and an interview with the patient's family and caseworker...
March 1997: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/16595355/differing-effects-of-antipsychotic-medications-on-substance-abuse-treatment-patients-with-co-occurring-psychotic-and-substance-abuse-disorders
#13
COMPARATIVE STUDY
Elizabeth B Stuyt, Terrie A Sajbel, Michael H Allen
This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and successful program completion as outcome measures. All patients with co-occurring substance dependence and schizophrenia or schizoaffective disorder treated with olanzapine, risperidone, ziprasidone, and typical depot neuroleptics from January 2001 to December 2003 (N = 55) are the subjects of this study. Patients stayed longer in treatment when taking risperidone (82 +/- 19 days) or ziprasidone (74 +/- 21 days) compared with olanzapine (44 +/- 30 days) or typicals (47 +/- 36 days)...
March 2006: American Journal on Addictions
https://www.readbyqxmd.com/read/15643098/adverse-cardiac-effects-associated-with-clozapine
#14
REVIEW
David B Merrill, G William Dec, Donald C Goff
OBJECTIVE: To review the published literature on serious adverse cardiac events associated with the atypical antipsychotic agent, clozapine, and to make recommendations for cardiac assessment of candidates for clozapine treatment and for monitoring of cardiac status after treatment is initiated. DATA SOURCES: We searched the PubMed and MEDLINE databases for articles published from 1970 to 2004 that contain the keywords "clozapine and myocarditis," "clozapine and cardiomyopathy," "clozapine and cardiotoxicity," "clozapine and sudden death" or "clozapine and mortality...
February 2005: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/23842012/termination-of-clozapine-treatment-due-to-medical-reasons-when-is-it-warranted-and-how-can-it-be-avoided
#15
REVIEW
Jimmi Nielsen, Christoph U Correll, Peter Manu, John M Kane
OBJECTIVE: To identify the outcome of potentially serious adverse effects of clozapine, particularly those frequently cited as reasons for clozapine discontinuation, and to characterize management strategies for adverse effects that do not warrant discontinuation. DATA SOURCES: A structured search was performed of PubMed and EMBASE from database inception until September 10, 2012, without any language restrictions, using clozapine as the search term. Reference lists of retrieved articles were cross-checked for additional relevant studies...
June 2013: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26417473/psychopathology-in-substance-use-disorder-patients-with-and-without-substance-induced-psychosis
#16
Simon Zhornitsky, Andràs Tikàsz, Élie Rizkallah, Jean-Pierre Chiasson, Stéphane Potvin
Background. Substance-induced psychotic disorder (SIPD) is a diagnosis constructed to distinguish substance-induced psychotic states from primary psychotic disorders. A number of studies have compared SIPD persons with primary psychotic patients, but there is little data on what differentiates substance use disorder (SUD) individuals with and without SIPD. Here, we compared psychopathology, sociodemographic variables, and substance use characteristics between SUD patients with and without SIPD. Methods. A retrospective chart review was conducted on newly admitted patients at a rehabilitation centre between 2007 and 2012...
2015: Journal of Addiction
https://www.readbyqxmd.com/read/26541815/comparative-effectiveness-of-clozapine-and-standard-antipsychotic-treatment-in-adults-with-schizophrenia
#17
COMPARATIVE STUDY
T Scott Stroup, Tobias Gerhard, Stephen Crystal, Cecilia Huang, Mark Olfson
OBJECTIVE: The authors compared the effectiveness of initiating treatment with either clozapine or a standard antipsychotic among adults with evidence of treatment-resistant schizophrenia in routine clinical practice. METHOD: U.S. national Medicaid data from 2001 to 2009 were used to examine treatment outcomes in a cohort of patients with schizophrenia and evidence of treatment resistance that initiated clozapine (N=3,123) and in a propensity score-matched cohort that initiated a standard antipsychotic (N=3,123)...
February 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26521019/treatment-of-early-non-response-in-patients-with-schizophrenia-assessing-the-efficacy-of-antipsychotic-dose-escalation
#18
RANDOMIZED CONTROLLED TRIAL
Antony Loebel, Leslie Citrome, Christoph U Correll, Jane Xu, Josephine Cucchiaro, John M Kane
BACKGROUND: Early non-response to antipsychotic treatment in patients with schizophrenia has been shown in multiple studies to predict poor response at short-term trial endpoint. Therefore, strategies to address the challenge of non-improvement early in the course of treatment are needed. A novel trial design was developed to assess the potential utility of antipsychotic dose escalation in patients with an inadequate initial treatment response. This design was embedded in a study intended to assess the efficacy of low dose lurasidone in patients with schizophrenia...
October 31, 2015: BMC Psychiatry
https://www.readbyqxmd.com/read/26481175/raise-ing-our-expectations-for-first-episode-psychosis
#19
EDITORIAL
Thomas R Insel
No abstract text is available yet for this article.
April 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26417330/clinical-pharmacology-of-atypical-antipsychotics-an-update
#20
REVIEW
M C Mauri, S Paletta, M Maffini, A Colasanti, F Dragogna, C Di Pace, A C Altamura
This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, que¬tiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine. A summary of their acute pharmacokinetics properties are also reported. Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine. Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine...
2014: EXCLI journal
label_collection
label_collection
2575
1
2
2015-10-14 22:29:24
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"